Amendments to the Claims

The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claim 31 (currently amended): A compound of the formula:







or a pharmaceutically acceptable salt thereof.

Claim 32 (currently amended): A method of inhibiting ~~one or more~~ cyclin dependent ~~kinases~~ kinase1 (CDK1) or cyclin dependent kinase 2 (CDK2), comprising administering ~~a therapeutically effective amount of~~ at least one compound of claim 31 ~~to a patient in need of such inhibition~~.

Claim 33 (currently amended): A method of treating one or more diseases ~~associated with a kinase~~ by inhibiting CDK1 or CDK2, comprising administering ~~a therapeutically effective amount of~~ at least one compound of claim 31 ~~to a patient in need of such treatment~~.

Claim 34 (currently amended): The method of claim 33, wherein said ~~kinase is~~ treatment is by inhibiting CDK2.

Claim 35 (currently amended): The method of claim 33, wherein said ~~kinase is mitogen activated protein kinase (MAPK/ERK)~~ treatment is by inhibiting CDK1.

Claim 36: Cancelled.

Claim 37 (original): The method of claim 33, wherein said disease is selected from the group consisting of:

cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas;

melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 38 (currently amended): A method of treating one or more diseases ~~associated with cyclin dependent kinase~~ by inhibiting CDK1 or CDK2, comprising administering to a mammal ~~in need of such treatment~~

an amount of a first compound, which is a compound of claim ~~1~~ 31, or a pharmaceutically acceptable salt thereof;

and

an amount of at least one second compound, said second compound being an anti-cancer agent;

wherein the amounts of the first compound and said second compound result in a therapeutic effect.

Claim 39 (original): The method of claim 38, further comprising radiation therapy.

Claim 40 (original): The method of claim 38, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan,

paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 41 (currently amended): A pharmaceutical composition comprising a ~~therapeutically effective amount of~~ at least one compound of claim 31 in combination with at least one pharmaceutically acceptable carrier.

Claim 42 (original): The pharmaceutical composition of claim 39, additionally comprising one or more anti-cancer agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine,

Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 43 (previously presented): A compound of claim 31 in purified form.

Claim 44 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 45 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 46 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 47 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 48 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 49 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 50 (previously presented): A compound of the formula:

9



or a pharmaceutically acceptable salt thereof.

Claim 51 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 52 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 53 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 54 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 55 (currently amended): A method of inhibiting ~~one or more cyclin dependent kinases~~ CDK1 or CDK2, comprising administering ~~a therapeutically effective amount of~~ at least one compound of any of claims 44-54 to a patient.

Claim 56 (currently amended): A method of treating one or more diseases ~~associated with a kinase~~ by inhibiting CDK1 or CDK2, comprising administering ~~a therapeutically effective amount of~~ at least one compound of any of claims 44-54 to a patient.

Claim 57 (previously presented) The method of claim 56, wherein said disease is selected from the group consisting of:

cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas;

melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 58 (currently amended): A method of treating one or more diseases ~~associated with cyclin dependent kinas~~ by inhibiting CDK1 or CDK2, comprising administering ~~to a mammal in need of such treatment~~

an amount of a first compound, which is a compound of claim 44-54, or a pharmaceutically acceptable salt thereof;

and

an amount of temozolomide;

wherein the amounts of the first compound and said temozolomide result in a therapeutic effect.

Claim 59 (original): The method of claim 58, further comprising radiation therapy.

Claim 60 (currently amended): A pharmaceutical composition comprising (i) ~~a therapeutically effective amount of~~ a compound of claim 44-54 or a pharmaceutically acceptable salt thereof, and (ii) temozolomide.

Claim 61 (currently amended): A method of inhibiting ~~one or more kinases~~ CDK1 or CDK2, comprising administering the pharmaceutical composition of claim 60.

Claim 62: cancelled.

Claim 63 (currently amended): A method of treating one or more diseases ~~associated with a kinase~~ by inhibiting CDK1 or CDK2, comprising administering the pharmaceutical composition of claim 60.

Claim 64 (previously presented): A method of treating a cancer, comprising administering the pharmaceutical composition of claim 60.

Claim 65 (currently amended): A method of treating a cancer, comprising administering ~~a therapeutically effective amount of~~ at least one compound of claim 31.

Claim 66 (previously presented): The method of claim 65, wherein said cancer is selected from the group consisting of:

cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 67 (currently amended): A method of treating a cancer, comprising administering ~~to a mammal in need of such treatment~~

an amount of a first compound, which is a compound of claim 31, or a pharmaceutically acceptable salt thereof;

and

an amount of at least one second compound, said second compound being an anti-cancer agent;

wherein the amounts of the first compound and said second compound result in a therapeutic effect.

Claim 68 (previously presented): The method of claim 67, further comprising radiation therapy.

Claim 69 (previously presented): The method of claim 67, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide,

Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 70 (currently amended): A method of treating a cancer, comprising administering (i) ~~a therapeutically effective amount of~~ at least one compound of claim 31, and (ii) temozolomide.